3 Drugs Stocks Dragging The Industry Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 38 points (0.2%) at 16,171 as of Friday, Feb. 21, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,939 issues advancing vs. 967 declining with 167 unchanged.

The Drugs industry currently sits up 1.2% versus the S&P 500, which is up 0.3%. On the negative front, top decliners within the industry include Actavis ( ACT), down 1.7%, and Allergan ( AGN), down 1.1%. Top gainers within the industry include Isis Pharmaceuticals ( ISIS), up 17.1%, Biogen Idec ( BIIB), up 3.9%, Regeneron Pharmaceuticals ( REGN), up 3.1%, Alexion Pharmaceuticals ( ALXN), up 1.9% and Amgen ( AMGN), up 1.2%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Hospira ( HSP) is one of the companies pushing the Drugs industry lower today. As of noon trading, Hospira is down $2.02 (-4.6%) to $41.96 on heavy volume. Thus far, 1.2 million shares of Hospira exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $41.88-$43.90 after having opened the day at $43.90 as compared to the previous trading day's close of $43.98.

Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and markets products worldwide. Hospira has a market cap of $7.3 billion and is part of the health care sector. Shares are up 6.1% year-to-date as of the close of trading on Thursday. Currently there are no analysts that rate Hospira a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Hospira as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Hospira Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, GlaxoSmithKline ( GSK) is down $0.23 (-0.4%) to $55.99 on average volume. Thus far, 982,264 shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $55.86-$56.28 after having opened the day at $56.23 as compared to the previous trading day's close of $56.22.

GlaxoSmithKline plc manufactures and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $135.2 billion and is part of the health care sector. Shares are up 4.3% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst that rates GlaxoSmithKline a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full GlaxoSmithKline Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Forest Laboratories ( FRX) is down $1.17 (-1.2%) to $96.13 on heavy volume. Thus far, 2.5 million shares of Forest Laboratories exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $95.19-$96.60 after having opened the day at $96.43 as compared to the previous trading day's close of $97.30.

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. Forest Laboratories has a market cap of $25.5 billion and is part of the health care sector. Shares are up 62.1% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts that rate Forest Laboratories a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Forest Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Forest Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists